Company Overview and News
Podcast | An evening walk down Dalal Street: Sensex recoups losses; Nifty holds 10,800 for 4th day
IOC 500325 HDFC 532960 532482 532480 BJJQY 500570 500010 RLNIY ASHOKLEY SBAZ AXB ALBK 532505 YYBKY 530965 AKLD AXBA BAJAJFINSV BAJFINANCE TCS HDFC AKLS ANDHRABANK DB PQRTY RELIANCE KTKBANK 532418 532978 533155 TTNQY JUBLFOOD IDBLZ 532215 GRANULES 532540 532187 AXISBANK RIGD JBLWY 500477 TATAMOTORS 500034 VALIANT YESBANK UBNC INDUSINDBK IBVENTURES IBN 532648 PETRONET 532522 AXBKY 532652 ICICIBANK 532174 526775 UCOBANK TTM
The country’s largest gas importer and regasifier Petronet LNG is having a good run, delivering strongly for the second year in a row. After nearly doubling in 2016-17 to ₹1,723 crore, the company’s consolidated profit has grown nearly 23 per cent Y-o-Y in 2017-18 to ₹2,110 crore.
IOC PQRTY TCHQY 530965 PETRONET 532755 532522 TECHM
NEW DELHI, May 24 (Reuters) - Indian gas utility GAIL (India) has switched its focus to short-term and spot deals for the purchase of liquefied natural gas (LNG) to meet rising demand and hedge against price volatility, its chairman said.
PQRTY PETRONET 532522
About 75 companies including Aries Agro, Atlas Cycles, Bajaj Electricals, CESC, Cosmo Films, Dhanlaxmi Bank, eClerx, Entertainment Network, Eros, Finolex, GE T&D, Godrej Industries, Grasim, GVK Power, HG Infra, IFCI, Indraprastha Gas, Jet Airways, Jain Irrigation, KPIT Tech, L&T Infotech, MEP Infra, Natco Pharma, Omaxe, Ramco Cements, Repco Home, Shipping Corp, SML Isuzu, Suntech Realty, Tata Motors and Vidhi Specialty will declare their quarter and full-year results on Wednesday.
GODREJIND PQRTY 524816 532617 532935 ATLASCYCLE 532514 IGL ARIES 508814 NATCOPHARM 505029 532180 500570 500031 TATAMOTORS RMCTY 505192 JETAIRWAYS PETRONET 532700 ENIL 532522 500260 SMLISUZU RAMCOCEM DHANBANK COSMOFILMS 500164 BAJAJELEC TTM
The Competition Commission of India on Tuesday approved the acquisition of US seed major Monsanto by Bayer AG. However, the clearance is subject to compliance with certain modifications, CCI said in a tweet. German conglomerate Bayer is preparing to close its $62.5-billion deal of Monsanto this quarter. With this clearance, the merger may enter the fast phase. Shareholders of Monsanto India will closely monitor the developments, both at the global and domestic levels.
524084 MONSANTO PQRTY PETRONET 532522
Shares of Zandu Realty will turn ex-date on Thursday for the proposed amalgamation with Emami Infrastructure. The latter will issue seven shares for every one share of ₹100 each held in Zandu Realty. Investors wishing to receive Emami shares need to own Zandu Realty shares by Wednesday, as the company has fixed May 25 as the record date. While the shares of Emami jumped 12.3 per cent to ₹278, those of Zandu gained 6.
533218 ZANDUREALT EMAMIINFRA PQRTY PETRONET 506720 532522
KEC International is part of RPG Group and an Indian Multinational EPC Major. Company has experience of over seven decades and has diversified business in 64 countries across five business verticals. KEC is presently executing 150+ projects out of which 29 are EPC projects in 29 counties. Company is well positioned across geography to gain from improving business outlook and signs of recovery across major global economy.
PQRTY 532714 PETRONET KEC 532522
May 22 Shares of chemicals and industrial materials maker Grasim Industries hit 10-1/2-month low, and technicals suggested further downside. The stock fell as much as 2.4 per cent to Rs 1,011, its lowest since July 3, 2017.
BAJAJ-AUTO GRASIM GRSXY GRSJY PQRTY 500300 532977 PETRONET 532522
May 22 Shares of Petronet LNG jumped on strong Q4 show. The stock rose as much as 2.8 per cent to Rs 216.10. The company, engaged in the sale of re-gasified liquefied natural gas, has posted 11 per cent rise in quarterly profit.
BAJAJ-AUTO DB PQRTY MS.PRE MS.PRF MS.PRG 532977 PETRONET MS.PRA 532522 MS.PRI MS.PRK TRI MS
The S&P BSE Sensex which started on a positive note on Monday failed to hold on to momentum and turned negative for the fifth consecutive day in a row. The Nifty50 which broke below its crucial support placed at 10,550 managed to hold on to 10,500 towards the close.
521248 500008 BHUSANSTL 533096 PQRTY 532617 517506 532538 532612 533278 ARJQY AMARAJABAT TTKPRESTIG 500470 CL UCLQY KITEX 500477 LHFLY 500570 TATAMOTORS CLNDY 500253 500055 ASHOKLEY YESBANK IBN INDOCO CLGQY JETAIRWAYS UCLQF 532648 YYBKY PETRONET ULTRACEMCO AKLD 532522 ICICIBANK TTST TATASTEEL TATLY LICHSGFIN 532174 ADANIPOWER AKLS COALINDIA TTM
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
PQRTY PETRONET 532522
Market Update: Benchmark indices ended lower for the fourth consecutive session, dragged by pharma, metals, auto stocks, HDFC twins and Reliance Industries.
500325 500008 BHUSANSTL 533096 ARJQY TTKPRESTIG CCL UCLQY BJJQY LHFLY 500570 500253 500055 RLNIY ASHOKLEY GLENMARK CLGQY JETAIRWAYS ULTRACEMCO AKLD BAJFINANCE TATASTEEL TATLY LICHSGFIN PPAP AKLS 521248 BALRAMCHIN PQRTY RELIANCE 532617 517506 532538 532934 519600 GLKQY AMARAJABAT 532654 500470 CL RIGD KITEX 500477 500038 TATAMOTORS 500034 MCLEODRUSS IBN UCLQF PETRONET 532522 ICICIBANK TTST 532296 532174 ADANIPOWER TTM
21h - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...